Sign in
Taking people in United StatesPhase 2

Donor Stem Cell Transplant for High-Risk Sickle Cell and Related Blood Disorders

Tests a donor stem cell transplant in people with sickle cell disease.

Key facts

Who runs it
Masonic Cancer Center, University of Minnesota
Where
Minneapolis, United StatesSee the site
Trial code
Registry title
Allo HSCT for High Risk Hemoglobinopathies
Status
Recruiting
Phase
Phase 2
People taking part
62 people, planned
Started
19 Nov 2024
Expected to end
1 Jun 2032
Type of study
Interventional, 5 groups
Treatments tested
  • Alemtuzumab
  • Total Body Irradiation
  • Cell Infusion
  • Thymoglobulin
  • Fludarabine
  • Busulfan
  • Cyclophosphamide
  • Sirolimus
  • Tacrolimus
  • Mycophenolate Mofetil
  • Plerixafor (mozobil)
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people with sickle cell disease, transfusion-dependent thalassemia, Diamond Blackfan Anemia or other non-cancer blood disorders who can have a donor stem cell transplant.

Age
Up to 55 years
Sex
All
Disease stage
Sickle cell disease (with a fully matched sibling donor, whatever the frequency or severity of symptoms), transfusion-dependent alpha- or beta-thalassemia, Diamond Blackfan Anemia, or other non-malignant blood disorders.

Main reasons for not taking part

  • Pregnant, breastfeeding or planning pregnancy during the study
  • HIV infection with a detectable viral load
  • Active, uncontrolled infection
  • Known allergy to any study component
  • Psychiatric illness or social situation that would limit following the study requirements

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Sickle Cell Disease (SCD)
  • SCD Patients with a fully matched sibling donor (MSD) irrespective of the frequency or severity of symptoms MSD transplant can be considered. Parents/patient must be counseled as to the risks and benefits and provide their voluntary informed consent
  • Transfusion Dependent Alpha- or Beta- Thalassemia
  • Diamond Blackfan Anemia
  • Other Non-Malignant Hematologic Disorders
  • Karnofsky ≥ 60%, Lansky play score ≥ 60. Patients with lower performance score can be considered based on study team's evaluation
  • Sexually active persons of childbearing potential or persons with partners of childbearing potential must agree to use a highly effective form of contraception during study treatment and for at least 4 months after the transplant

Who cannot take part

  • HIV infection with a detectable viral load. All HIV+ patients must be evaluated by infectious disease (ID) and an HIV management plan established prior to transplantation
  • Active, uncontrolled infection - infection that is stable or improving after 1 week of appropriate therapy (4 weeks for presumed or documented fungal infections) will be permitted
  • Known allergy to any of the study components
  • Psychiatric illness/social situations that, in the judgement of the enrolling Investigator, would limit compliance with study requirements
  • Other illness or a medical issue that, in the judgement of the enrolling Investigator, would exclude the patient from participating in this study
  • Pregnant, breastfeeding or intending to become pregnant during the study. Persons of childbearing potential must have a negative pregnancy test (serum or urine) within 30 days of the start of treatment

Where in United States

  • Masonic Cancer CenterMinneapolis, United StatesContact: Ashish Gupta, MBBS, MPHTaking people

About the trial

What the trial wants to find out

A single center, open label, interventional, phase II trial for donor transplant for high risk hemoglobinopathies and other red cell transfusion dependent disorders utilizing allogeneic hematopoietic stem cell transplantation (HSCT) regimens.

The 5 groups in the trial

  • Arm A - ClosedTreatment being tested

    Arm A Matched sib regimen - Age 6 -55 (per physician preference for patients over 6) Campath/TBI

    Treatment: Alemtuzumab, Total Body Irradiation, Cell Infusion, Sirolimus, and Mycophenolate Mofetil

  • Arm BTreatment being tested

    Arm B Matched sib regimen - 0-55 (per physician preference for patients over 6) ATG/Flu/Bu

    Treatment: Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Tacrolimus, and Mycophenolate Mofetil

  • Arm CTreatment being tested

    Arm C Fully Matched unrelated donor (MUD)- - 0-55 years; ATG/Flu/Bu

    Treatment: Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Tacrolimus, Mycophenolate Mofetil, and Plerixafor (mozobil)

  • Arm DTreatment being tested

    Arm D: Haploindentical or mismatched unrelated donors (MMUD) - 0-55 years; ATG/Thiotepa/Cyclophosphamide/MESNA/Flu/TBI

    Treatment: Sirolimus, Tacrolimus, and Plerixafor (mozobil)

  • Arm ETreatment being tested

    Matched sib regimen - Age 6-55 (per physician preference for patients over 6) Campath/TBI with peripheral blood stem cell graft

    Treatment: Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Cyclophosphamide, Sirolimus, Tacrolimus, and Mycophenolate Mofetil

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders
Plain-language title
Donor Stem Cell Transplant for High-Risk Sickle Cell and Related Blood DisordersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 June 2026